Objective Atopic dermatitis (AD) is a chronic pruritic inflammatory skin disease with
substantial patient and population burdens. A number of comorbid health problems occur in …

Atopic dermatitis is a common, chronic, immune-mediated disease associated with several
comorbidities. Elevated levels of T helper (Th) 2, Th22, and also some Th1 and Th17 …

The evidence‐and consensus‐based guideline on atopic eczema was developed in
accordance with the EuroGuiDerm Guideline and Consensus Statement Development …

Background Abrocitinib, an oral selective Janus kinase 1 inhibitor, was effective and well
tolerated in adults with moderate-to-severe atopic dermatitis in a phase 2b trial. We aimed to …

Importance Abrocitinib, an oral, once-daily Janus kinase 1 selective inhibitor, was effective
and well tolerated in a phase 3 monotherapy trial of patients with moderate-to-severe atopic …

Background Studies found associations between atopic dermatitis (AD) and various
comorbidities. Objective To appraise evidence of the association between AD and …

Background Primary (week 16) results from the ongoing phase 3, double-blind AD Up study
(NCT03568318) demonstrate a positive benefit–risk profile for upadacitinib+ topical …

Background Upadacitinib is an oral Janus kinase (JAK) inhibitor with greater inhibitory
potency for JAK1 than JAK2, JAK3, and tyrosine kinase 2. We aimed to assess the efficacy …

Atopic dermatitis (AD) is a common disease that is associated with atopic and nonatopic
comorbidities. There has been a growing interest in this area of AD, because presence or …

Background Eczema and food allergy are common health conditions that usually begin in
early childhood and often occur in the same people. They can be associated with an …